Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Generex Biotechnology Corp. OSMOS Clinical Research, Inc PSI Pharma Support Intl Nextrials, Inc. eResearch Technology, Inc. Hoffmann-La Roche ACM Pivotal Global Central Laboratory |
---|---|
Information provided by: | Generex Biotechnology Corp. |
ClinicalTrials.gov Identifier: | NCT00668850 |
To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus |
Drug: Generex Oral-lyn™ Drug: Regular human insulin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-Lyn™ Spray and Injected Human Insulin In Subjects With Type-1 Diabetes Mellitus |
Estimated Enrollment: | 750 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
|
Drug: Generex Oral-lyn™
Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
|
2: Active Comparator
Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
|
Drug: Regular human insulin
Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
|
This is a 26 week open-label, randomized, multi-center, active comparator study to compare oral spray insulin (Generex Oral-lyn™) with regular human insulin therapy as measured by HbA1c, and number of hypoglycaemic episodes in type-1 diabetes mellitus subject. All subjects will be on BID NPH intermediate acting insulin therapy. If subject is using long acting insulin (Glargine, Detemir, etc.), he/she must be switched to NPH intermediate acting insulin. If on insulin analogue (Novolog, Lispro, Aspart, Aphidra, Glulisine, or any other analogue available in the subject's geographical area), the subject must be switched to regular human insulin 3 times a day.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Kirill Soldatov | 7-812-320-3855 | Kirill.Soldatov@psi-cro.com |
Study Chair: | Gerald Bernstein,, MD | Generex Biotechnology Corp. |
Study Director: | Jaime Davidson, MD | Generex Biotechnology Corp. |
Principal Investigator: | Philip Raskin, MD | University of Texas Southwestern Medical Center at Dallas |
Responsible Party: | Generex Biotechnology Corp. ( George E. Markus ) |
Study ID Numbers: | GEN-084-OL |
Study First Received: | April 24, 2008 |
Last Updated: | October 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00668850 |
Health Authority: | United States: Food and Drug Administration |
Autoimmune Diseases Metabolic Diseases Diabetes Mellitus, Type 1 Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Insulin, Isophane Insulin |
Hypoglycemic Agents Immune System Diseases Physiological Effects of Drugs Pharmacologic Actions |